PE20001467A1 - Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina - Google Patents

Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina

Info

Publication number
PE20001467A1
PE20001467A1 PE2000000125A PE0001252000A PE20001467A1 PE 20001467 A1 PE20001467 A1 PE 20001467A1 PE 2000000125 A PE2000000125 A PE 2000000125A PE 0001252000 A PE0001252000 A PE 0001252000A PE 20001467 A1 PE20001467 A1 PE 20001467A1
Authority
PE
Peru
Prior art keywords
alkyl
phenylpyridine
derivatives
alcoxy
trifluoromethyl
Prior art date
Application number
PE2000000125A
Other languages
English (en)
Spanish (es)
Inventor
Quirico Branca
Michael Bos
Guido Galley
Heinz Stadler
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Thierry Godel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20001467A1 publication Critical patent/PE20001467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2000000125A 1999-02-24 2000-02-18 Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina PE20001467A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689 1999-11-29

Publications (1)

Publication Number Publication Date
PE20001467A1 true PE20001467A1 (es) 2000-12-20

Family

ID=26152908

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000125A PE20001467A1 (es) 1999-02-24 2000-02-18 Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina

Country Status (54)

Country Link
US (2) US6297375B1 (en:Method)
EP (2) EP1035115B1 (en:Method)
JP (1) JP3399900B2 (en:Method)
KR (1) KR100384904B1 (en:Method)
CN (1) CN1142144C (en:Method)
AR (2) AR029614A1 (en:Method)
AT (2) ATE496032T1 (en:Method)
AU (1) AU767048B2 (en:Method)
BE (1) BE2015C057I2 (en:Method)
BG (1) BG64554B1 (en:Method)
BR (1) BRPI0000908B8 (en:Method)
CA (1) CA2299139C (en:Method)
CY (3) CY1111317T1 (en:Method)
CZ (1) CZ300596B6 (en:Method)
DE (3) DE60014216T2 (en:Method)
DK (2) DK1035115T3 (en:Method)
EA (1) EA003673B1 (en:Method)
EG (1) EG23817A (en:Method)
ES (3) ES2359235T3 (en:Method)
FR (2) FR2790473B1 (en:Method)
GB (1) GB2347422A (en:Method)
GE (1) GEP20022676B (en:Method)
GT (1) GT200000017A (en:Method)
HR (2) HRP20000097B1 (en:Method)
HU (1) HU227629B1 (en:Method)
IL (1) IL134654A (en:Method)
IS (1) IS2116B (en:Method)
IT (1) IT1320763B1 (en:Method)
JO (1) JO2294B1 (en:Method)
LT (1) LTC1035115I2 (en:Method)
LU (1) LU92745I2 (en:Method)
MA (1) MA26722A1 (en:Method)
ME (1) ME00593B (en:Method)
MY (2) MY147451A (en:Method)
NL (1) NL300758I1 (en:Method)
NO (1) NO315554B1 (en:Method)
NZ (1) NZ502948A (en:Method)
OA (1) OA11680A (en:Method)
PA (1) PA8491101A1 (en:Method)
PE (1) PE20001467A1 (en:Method)
PL (1) PL217311B1 (en:Method)
PT (2) PT1394150E (en:Method)
RS (3) RS20080562A (en:Method)
SE (1) SE1035115T5 (en:Method)
SG (1) SG91856A1 (en:Method)
SI (1) SI1035115T1 (en:Method)
SK (2) SK287911B6 (en:Method)
SV (1) SV2002000024A (en:Method)
TN (1) TNSN00032A1 (en:Method)
TR (1) TR200000520A3 (en:Method)
TW (1) TWI288746B (en:Method)
UA (1) UA71547C2 (en:Method)
UY (1) UY32314A (en:Method)
ZA (1) ZA200000894B (en:Method)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058640A2 (en) * 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Mct-1, a human oncogene
WO2000050398A2 (en) 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
ES2208205T3 (es) * 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 ă‚»ăƒłăƒˆăƒ©ăƒ«çĄć­æ ȘćŒäŒšç€Ÿ ć…‰ć­ŠæŽ»æ€§Î±âˆ’ăƒĄăƒăƒ«âˆ’ăƒ“ă‚čâˆ’ïŒ“ă€ïŒ•âˆ’ïŒˆăƒˆăƒȘăƒ•ăƒ«ă‚Șăƒ­ăƒĄăƒăƒ«ïŒ‰ăƒ™ăƒłă‚žăƒ«ă‚ąăƒŸăƒłăźèŁœé€ æ–čæł•
EP1303490B1 (en) * 2000-07-14 2008-07-09 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
AU2002216085B8 (en) * 2000-12-14 2006-03-02 F. Hoffmann-La Roche Ag Self Emulsifying Lipid Matrix (SELM)
US6531597B2 (en) * 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US7112593B2 (en) 2001-03-27 2006-09-26 Eisai Co., Ltd. N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
DK1385577T3 (da) * 2001-04-23 2006-08-21 Hoffmann La Roche Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi
DK1395289T3 (da) * 2001-06-07 2011-03-28 Christine Dr Sang Behandling af neuropatisk smerte med en N-methyl-D-aspartat- (NMDA-)receptorantagonist
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
EP1427397B1 (en) * 2001-09-10 2008-02-13 F. Hoffmann-La Roche Ag Oily thixotropic formulations
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
JP2006508061A (ja) 2002-09-20 2006-03-09 ăƒ•ă‚Ąă‚€ă‚¶ăƒŒăƒ»ăƒ—ăƒ­ăƒ€ă‚Żăƒ„ăƒ»ă‚€ăƒłă‚Ż スă‚čトロă‚Čン揗ćźčäœ“ă«ćŻŸă™ă‚‹ă‚ąăƒŸăƒ‰ăŠă‚ˆăłă‚čăƒ«ăƒ›ăƒłă‚ąăƒŸăƒ‰ăƒȘガンド
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
DE60329415D1 (de) 2002-12-06 2009-11-05 Purdue Research Foundation Pyridine zur behandlung von verletztemsÀugetiernervengewebe
ATE366576T1 (de) 2003-01-31 2007-08-15 Hoffmann La Roche Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
WO2005002577A1 (en) 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
TWI280239B (en) * 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
PL1648874T3 (pl) 2003-07-30 2012-04-30 Xenon Pharmaceuticals Inc Pochodne piperazyny i ich zastosowanie jako ƛrodków leczniczych
WO2007056341A1 (en) * 2005-11-08 2007-05-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 혾프만-띌 ëĄœìŠˆ 아êȌ ïŒźïœ‹-1 수용ìČŽ Ꞟ항제의 합성에 있얎서 쀑간ìČŽëĄœì„œì‚Źìš©ë˜ëŠ” ìčŽë„Žëł”ìŠ€ì•„ëŻžë“œ í”ŒëŠŹë”˜ 유도ìČŽì˜ ì œìĄ° ë°©ëȕ
JP4580426B2 (ja) * 2004-07-06 2010-11-10 ă‚šăƒ•ïŒŽăƒ›ăƒ•ăƒžăƒłâˆ’ăƒ© ăƒ­ă‚·ăƒ„ ă‚ąăƒŒă‚ČăƒŒ ïŒźïœ‹âˆ’ïŒ‘ć—ćźčäœ“æ‹źæŠ—è–Źăźćˆæˆă«ăŠă„ăŠäž­é–“äœ“ăšă—ăŠäœżç”šă•ă‚Œă‚‹ă‚«ăƒ«ăƒœă‚­ă‚”ăƒŸăƒ‰èȘ˜ć°Žäœ“ăźèŁœé€ æ–čæł•
ES2380020T3 (es) * 2004-07-06 2012-05-07 Xenon Pharmaceuticals Inc. Derivados de nicotinamida y su uso como agentes terapéuticos
WO2006013205A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP2008513515A (ja) 2004-09-20 2008-05-01 ă‚ŒăƒŽăƒłăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ 耇玠環èȘ˜ć°Žäœ“ăŠă‚ˆăłæČ»ç™‚è–Źăšă—ăŠăźăă‚Œă‚‰ăźäœżç”š
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocÏclicos e sua utilização como inibidores da estearoil-coa desaturase
BRPI0515488A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocĂŹclicos e seu uso como agentes terapĂȘuticos
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocÏclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
WO2006101521A2 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17ÎČ-hydroxysteroid dehydrogenase 3
WO2006060174A1 (en) * 2004-11-15 2006-06-08 Honeywell International Inc. Isocyanate-based polymer foams with nano-scale materials
BRPI0606843A2 (pt) * 2005-02-22 2009-07-21 Hoffmann La Roche antagonistas de nk 1
AU2006216566A1 (en) * 2005-02-24 2006-08-31 Janssen Pharmaceutica N.V. Novel pyridine derivatives as potassium ion channel openers
NZ560232A (en) 2005-02-25 2010-11-26 Hoffmann La Roche Tablets with improved drug substance dispersibility
AU2006226665B2 (en) * 2005-03-23 2011-01-27 Helsinn Healthcare S.A. Metabolites for NK-I antagonists for emesis
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
MX2008002019A (es) * 2005-08-11 2008-04-16 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
MY145713A (en) 2005-09-09 2012-03-30 Smithkline Beecham Corp Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders
JP5523706B2 (ja) * 2005-09-23 2014-06-18 ă‚šăƒ•ïŒŽăƒ›ăƒ•ăƒžăƒłâˆ’ăƒ© ăƒ­ă‚·ăƒ„ ă‚ąăƒŒă‚ČăƒŒ æ–°èŠæŠ•è–Źé…ćˆç‰©
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) * 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
ES2659364T3 (es) 2006-04-07 2018-03-15 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de uniĂłn a ATP
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
WO2009073757A1 (en) 2007-12-07 2009-06-11 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
PT2639223T (pt) * 2007-12-07 2017-05-08 Vertex Pharma Processos para produção de åcidos cicloalquilcarboxamido-piridinabenzoicos
JP2011512413A (ja) * 2008-02-19 2011-04-21 ă‚°ăƒ©ă‚Żă‚œă‚čミă‚čă‚Żăƒ©ă‚€ăƒłăƒ»ăƒȘăƒŸăƒ†ăƒƒăƒ‰ăƒ»ăƒ©ă‚€ă‚ąăƒ“ăƒȘăƒ†ă‚Łăƒ»ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ïŒŠïœïœ‹ăźé˜»ćźłć‰€ăšă—ăŠăźă‚ąăƒ‹ăƒȘノピăƒȘゾン
CN102245573B (zh) 2008-02-28 2013-11-20 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž 䜜äžșcftrè°ƒèŠ‚ć‰‚çš„æ‚èŠłćŸșèĄç”Ÿç‰©
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
MX2012002369A (es) * 2009-08-27 2012-03-29 Glaxosmithkline Llc Formas de anhidrato de un derivado de piridina.
GEP20156226B (en) 2009-11-18 2015-01-26 Helsinn Healthcare Sa Ch Compositions for treating centrally mediated nausea and vomiting
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2579965T3 (es) 2010-04-07 2016-08-17 Vertex Pharmaceuticals Incorporated Las formas sĂłlidas de 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) Ciclopropano carboxamida)-3-metilpiridin-2-il)benzoico
CN102917692A (zh) 2010-04-07 2013-02-06 ćŒ—ç‰čć…‹æ–ŻèŻć“æœ‰é™ć…Źćž 3-(6-(1-(2,2-äșŒæ°Ÿè‹Żćč¶[d][1,3]äșŒæ°§æ‚çŽŻæˆŠçƒŻ-5-ćŸș)环侙ç”Č酰èƒșćŸș)-3-ç”ČćŸș搥敶-2-ćŸș)è‹Żç”Čé…žçš„èŻç‰©ç»„ćˆç‰©ć’Œć…¶ç»™èŻæ–čæł•
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
WO2013019621A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013019635A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
HUE030811T2 (hu) 2011-10-18 2017-05-29 Helsinn Healthcare Sa Netupitant Ă©s palonosetron terĂĄpiĂĄs kombinĂĄciĂłi
RU2640420C2 (ru) 2011-11-08 2018-01-09 ВДртДĐșс Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșалз Đ˜ĐœĐșĐŸŃ€ĐżĐŸŃ€Đ”ĐčтДЎ ĐœĐŸĐŽŃƒĐ»ŃŃ‚ĐŸŃ€Ń‹ Ń‚Ń€Đ°ĐœŃĐżĐŸŃ€Ń‚Đ”Ń€ĐŸĐČ Đ°Ń‚Ń„-сĐČŃĐ·Ń‹ĐČающДĐč ĐșассДты
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
CN105745198B (zh) * 2013-11-08 2018-09-21 æ©˜ç”ŸèŻć“ć·„äžšæ ȘćŒäŒšç€Ÿ 矧ç”ČćŸșć“Œć•¶èĄç”Ÿç‰©
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
UA124567C2 (uk) 2014-04-15 2021-10-13 ВДртДĐșс Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșалз Đ†ĐœĐșĐŸŃ€ĐżĐŸŃ€Đ”ĐčтДЎ Đ€Đ°Ń€ĐŒĐ°Ń†Đ”ĐČŃ‚ĐžŃ‡ĐœŃ– ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†Ń–Ń— ĐŽĐ»Ń ліĐșуĐČĐ°ĐœĐœŃ Đ·Đ°Ń…ĐČĐŸŃ€ŃŽĐČĐ°ĐœŃŒ, ĐŸĐżĐŸŃĐ”Ń€Đ”ĐŽĐșĐŸĐČĐ°ĐœĐžŃ… ĐŒŃƒĐșĐŸĐČŃ–ŃŃ†ĐžĐŽĐŸĐ·ĐœĐžĐŒ Ń€Đ”ĐłŃƒĐ»ŃŃ‚ĐŸŃ€ĐŸĐŒ Ń‚Ń€Đ°ĐœŃĐŒĐ”ĐŒĐ±Ń€Đ°ĐœĐœĐŸŃ— ĐżŃ€ĐŸĐČŃ–ĐŽĐœĐŸŃŃ‚Ń–
US20150315149A1 (en) * 2014-05-05 2015-11-05 Apicore Us Llc Methods of making netupitant and intermediates thereof
TWI649307B (zh) * 2014-05-07 2019-02-01 æ—„ć•†æ©˜ç”Ÿè—„ć“ć·„æ„­è‚Ąä»œæœ‰é™ć…Źćž Cyclohexylpyridine derivative
TW201613888A (en) * 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
PT3221692T (pt) 2014-11-18 2021-09-10 Vertex Pharma Processo de realização de testagem de alta produtividade por cromatografia lĂ­quida de alta eficiĂȘncia
JP6891385B2 (ja) 2015-03-04 2021-06-18 ăƒăƒłăƒ€ăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ïŒ¶ïœïœŽïœ„ïœ   ăƒˆăƒ©ă‚žăƒ”ă‚żăƒłăƒˆă«ă‚ˆă‚‹æȻ療æ–čæł•
CN105061303A (zh) * 2015-08-03 2015-11-18 æˆéƒœæŹŁæ·é«˜æ–°æŠ€æœŻćŒ€ć‘æœ‰é™ć…Źćž äž€ç§ćˆ¶ć€‡ć„ˆćŠ„ćĄćŠć…łé”źäž­é—Žäœ“n-ç”ČćŸș-4-(2-ç”ČćŸșè‹ŻćŸș)-6-(4-ç”ČćŸș-1-擌ć—ȘćŸș)-3-搥敶èƒș的新æ–čæł•
CA2996717A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CN108368062A (zh) * 2015-12-07 2018-08-03 æ©˜ç”ŸèŻć“ć·„äžšæ ȘćŒäŒšç€Ÿ Nk1ć—äœ“æ‹źæŠ—ć‰‚
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 çŸŽć•†äșžćŸ·ćˆ©ć…‹æ–Żć…Źćž 䜜çˆČ非慹èș«ïœ”ïœ‡ïœ’ïŒ•äżƒæ•ˆćŠ‘äč‹ç¶“ć–ä»Łäč‹4-è‹ŻćŸșćĄć•¶ćŒ–ćˆç‰©
CN106892864A (zh) * 2015-12-21 2017-06-27 äžŠæ”·ç§‘èƒœèŻç‰©ç ”ć‘æœ‰é™ć…Źćž äž€ç§ć„ˆćŠ„çšźćŠæžžçŠ»çą±çš„æ™¶ćž‹aćŠć…¶ćˆ¶ć€‡æ–čæł•
AU2016377658B2 (en) * 2015-12-22 2022-09-29 Endosome Therapeutics, Inc. Tripartite modulators of endosomal G protein-coupled receptors
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CN111032158A (zh) 2017-06-30 2020-04-17 才思æČ»ç–—ć…Źćž 甹äșŽæČ»ç–—æŠ‘éƒçš„nk-1æ‹źæŠ—ć‰‚ç»„ćˆç‰©ć’Œæ–čæł•
CN109384712B (zh) * 2017-08-14 2021-05-07 挗äșŹćźœćŽšćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž é¶ć‘nk1ć—äœ“æ‹źæŠ—ć‰‚ćŠć…¶ćœšćŒ–ç–—æ‰€è‡Žæ¶ćżƒă€ć‘•ćæȻ疗䞭的ćș”甚
WO2019038656A1 (en) 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
EP3856338B1 (en) * 2018-09-28 2024-11-06 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
EP3902793A4 (en) * 2018-12-24 2022-09-07 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) MANUFACTURE OF A CHEMICAL COMPOUND, NEW FORM OF SALT, AND ASSOCIATED THERAPEUTIC USES
CN112174881B (zh) * 2019-07-04 2022-06-21 äžŠæ”·æŁźèŸ‰ćŒ»èŻæœ‰é™ć…Źćž äž€ç§ć„ˆćŠ„ćŒčćŠçš„èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•
CN114466683A (zh) * 2019-08-23 2022-05-10 ć°€æ–Żç‰čæ‹‰é‡Œæ–Żćˆ¶èŻæœ‰é™ć…ŹćžïŒˆä»„æ™źé›·èˆ’æ‹‰çșœçœ—䜜äžșć•†ć·ïŒ‰ æȻ疗æ–čæł•ćŠć…¶ç”šé€”
CN115427033B (zh) 2020-04-03 2024-08-09 ć°Œć°”ćŒ»ç–—æœ‰é™ć…Źćž 甹äșŽæȻ疗选è‡Șè„“æŻ’ç—‡ă€è„“æŻ’ç—‡äŒ‘ć…‹ă€æ€„æ€§ć‘ŒćžçȘ˜èż«ç»ŒćˆćŸ(ards)æˆ–ć€šć™šćź˜ćŠŸèƒœéšœçąç»ŒćˆćŸ(mods)çš„ç–Ÿç—…çš„nk-1ć—äœ“æ‹źæŠ—ć‰‚
AU2021285503A1 (en) 2020-06-02 2022-12-08 Nerre Therapeutics Limited Neurokinin (NK)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
CN120693151A (zh) 2022-12-12 2025-09-23 é˜żć°”ćŒ—é›·ćŸ·.E.è’‚èŠŹć·Žè”«ć°”æœ‰é™èŽŁä»»äž€ćˆć…Źćž ćŒ…æ‹Źć„ˆćŠ„ćŒčćŠć’Œćž•æŽ›èŻșćžçŒçš„ć›șćźšć‰‚é‡ç»„ćˆ
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에넎 위람 신규한 ìŽì†Œë¶€í‹°ëŒëŻžë“œë„˜ì˜ ì œìĄ°ë°©ëȕ
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에넎 위람 ìŽì†Œë¶€í‹°ëŒëŻžë“œ 유도ìČŽì˜ 신규한 ì œìĄ°ë°©ëȕ
DE3366369D1 (en) 1982-03-17 1986-10-30 Smith Kline French Lab Pyridine derivatives
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
AU4718093A (en) 1992-07-31 1994-03-03 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
EP0737192B1 (en) * 1993-12-29 2001-10-31 Merck Sharp & Dohme Ltd. Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
JPH10501228A (ja) 1994-06-06 1998-02-03 ăƒŻăƒŒăƒŠăƒŒâˆ’ăƒ©ăƒłăƒăƒŒăƒˆăƒ»ă‚łăƒłăƒ‘ăƒ‹ăƒŒ ă‚żă‚­ă‚­ăƒ‹ăƒłïŒˆïœŽïœ‹â–Čäž‹ïŒ‘â–ŒïŒ‰ć—ćźčäœ“ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čト
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
NO309272B1 (no) * 1995-03-24 2001-01-08 Takeda Chemical Industries Ltd Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
KR100313641B1 (ko) 1996-03-29 2002-02-19 디. 제읎. 우드, 슀플êȔ 알렌 제읎 6-íŽ˜ë‹í”ŒëŠŹë”œ-2-ì•„ëŻŒìœ ë„ìČŽ
AU4885097A (en) 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
WO2000050398A2 (en) * 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
ES2208205T3 (es) * 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives

Also Published As

Publication number Publication date
GB2347422A (en) 2000-09-06
AR062949A2 (es) 2008-12-17
HUP0000748A2 (en) 2001-03-28
IL134654A (en) 2011-03-31
NL300758I2 (en:Method) 2015-12-22
MEP5709A (en) 2011-12-20
CY2015041I2 (el) 2016-06-22
AR029614A1 (es) 2003-07-10
GEP20022676B (en) 2002-04-25
KR20000062599A (ko) 2000-10-25
ATE496032T1 (de) 2011-02-15
EP1035115B1 (en) 2004-09-29
TWI288746B (en) 2007-10-21
LU92745I2 (fr) 2015-08-17
PL338598A1 (en) 2000-08-28
SE1035115T5 (sv) 2015-08-04
IL134654A0 (en) 2001-04-30
OA11680A (fr) 2005-01-12
NL300758I1 (en:Method) 2015-12-22
BR0000908A (pt) 2000-09-12
LTC1035115I2 (lt) 2017-04-10
CZ300596B6 (cs) 2009-06-24
MY147451A (en) 2012-12-14
FR15C0049I2 (fr) 2016-02-12
GB0003908D0 (en) 2000-04-05
HK1031223A1 (en) 2001-06-08
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (en) 2015-08-31
ZA200000894B (en) 2000-08-24
ES2171109B2 (es) 2003-09-16
US6297375B1 (en) 2001-10-02
ATE277905T1 (de) 2004-10-15
MA26722A1 (fr) 2004-12-20
DK1394150T3 (da) 2011-03-21
SI1035115T1 (en) 2005-02-28
CY2015041I1 (el) 2016-06-22
RS20080562A (en) 2009-09-08
GT200000017A (es) 2001-08-15
FR2790473B1 (fr) 2004-04-02
CA2299139A1 (en) 2000-08-24
SG91856A1 (en) 2002-10-15
JP2000247957A (ja) 2000-09-12
SV2002000024A (es) 2002-01-23
KR100384904B1 (ko) 2003-05-22
US6479483B2 (en) 2002-11-12
PT1035115E (pt) 2005-01-31
NO20000885L (no) 2000-08-25
EP1394150B1 (en) 2011-01-19
SK2352000A3 (en) 2000-09-12
ITMI20000328A1 (it) 2001-08-23
IT1320763B1 (it) 2003-12-10
DE60014216D1 (de) 2004-11-04
ITMI20000328A0 (it) 2000-02-23
US20020091265A1 (en) 2002-07-11
BR0000908B1 (pt) 2013-09-24
AU767048B2 (en) 2003-10-30
EA003673B1 (ru) 2003-08-28
TR200000520A2 (tr) 2001-06-21
DE60014216T2 (de) 2006-03-02
MY123648A (en) 2006-05-31
EA200000155A2 (ru) 2000-08-28
UY32314A (es) 2010-02-26
ES2226622T3 (es) 2005-04-01
HRP20000097B1 (en) 2008-12-31
CN1270959A (zh) 2000-10-25
BE2015C057I2 (en:Method) 2019-03-06
FR15C0049I1 (fr) 2015-08-28
AU1946800A (en) 2000-08-31
HU227629B1 (en) 2011-10-28
HU0000748D0 (en) 2000-04-28
IS5381A (is) 2000-08-25
HRP20080306B1 (hr) 2015-01-30
SK287911B6 (sk) 2012-03-02
JP3399900B2 (ja) 2003-04-21
ES2359235T3 (es) 2011-05-19
RS50194B (sr) 2009-05-06
HRP20000097A2 (en) 2001-10-31
BRPI0000908B8 (pt) 2021-05-25
EP1394150A1 (en) 2004-03-03
CA2299139C (en) 2011-03-29
EA200000155A3 (ru) 2000-12-25
BG104187A (en) 2000-11-30
IS2116B (is) 2006-06-15
HUP0000748A3 (en) 2003-12-29
BG64554B1 (bg) 2005-07-29
CY1111317T1 (el) 2015-08-05
PT1394150E (pt) 2011-02-17
DK1035115T3 (da) 2005-01-24
DE60045564D1 (de) 2011-03-03
SK287912B6 (sk) 2012-03-02
ES2171109A1 (es) 2002-08-16
CY2015042I1 (el) 2016-06-22
SE1035115T3 (sv) 2005-01-18
UA71547C2 (uk) 2004-12-15
NZ502948A (en) 2001-09-28
ME00593B (me) 2015-08-31
TNSN00032A1 (fr) 2005-11-10
DE10008042A1 (de) 2000-08-31
CN1142144C (zh) 2004-03-17
PA8491101A1 (es) 2001-04-30
JO2294B1 (en) 2005-09-12
NO20000885D0 (no) 2000-02-23
FR2790473A1 (fr) 2000-09-08
HRP20080306A2 (en) 2008-11-30
TR200000520A3 (tr) 2001-06-21
NO315554B1 (no) 2003-09-22
EG23817A (en) 2007-09-19
EP1035115A1 (en) 2000-09-13
PL217311B1 (pl) 2014-07-31
CZ2000609A3 (cs) 2001-01-17
YU9500A (sh) 2002-11-15

Similar Documents

Publication Publication Date Title
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20010009A1 (es) Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
PE20000325A1 (es) Derivados de 2-ariletil-(piperidin-4-ilmetil)amina
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
UY27029A1 (es) Nuevos derivados de pirazolpiridina sustituidos con piridina
DE69120100D1 (de) Annelierte Thiophen-Derivate, ihre Herstellung und Verwendung
PE20001551A1 (es) Derivados de eter biarilico como inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc
NO20053960L (no) Piperidin-benzensulfonamidderivater
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacĂȘutico
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE106499A1 (es) Antagonistas del receptor ccr-3
AR029616A1 (es) Compuestos derivados de 3-fenil-piridina, su uso, un proceso para prepararlos y medicamentos que los contienen
AR058618A1 (es) "( indazol -5- il) - pirazinas y (1,3- dihidro- indol-2- ona) - pirazinas para el tratamiento de enfermedades y afecciones mediadas por rho quinasa
PE20000170A1 (es) Derivados benzosulfonas
DK0979821T3 (da) Tricykliske forbindelser
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
PE20050465A1 (es) Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3
ES2113081T3 (es) 1,4-benzotiazepinas utiles como agentes neurologicos.
PE20040772A1 (es) Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20040757A1 (es) Derivados de benzoxazina

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term